- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06364839
Liver Transplantation for Hepatocellular Carcinoma Arising in Non-cirrhotic Liver: a Propensity Score-matched Retrospective Cohort Study of Two National Databases
Background: Majority of liver transplantation (LT) recipients for hepatocellular carcinoma (HCC) were concomitant with liver cirrhosis, while few researches focusing on recipients without cirrhosis. Here we aim to investigate the prognosis of non-cirrhosis HCC recipients, expecting to provide theoretical basis for further improvement of these patients.
Methods: This retrospective study analyze outcomes between adult HCC recipients arising in non-cirrhotic and cirrhotic liver from two national databases (CLTR and UNOS, January 2015 to December 2020). Based on important variables, 1:2 and 1:1 propensity score matching (PSM) were performed respectively.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Xiao Xu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- liver transplants, performed from January 2015 to December 2020
Exclusion Criteria:
- pediatric LT; LT for non-tumor lesions; LT for other malignant tumors (cholangiocarcinoma, carcinoma of gallbladder, mixed carcinoma, and secondary tumors); re-transplantation or combined liver-kidney transplantation; incomplete laboratory or clinical data; death within 1 week due to post-operative hemorrhage after LT.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Postoperative complications were evaluated by postoperative imaging and serological examination
Time Frame: 3 months
|
Including rejection after liver transplantation, vascular complications, new metabolic diseases and so on
|
3 months
|
The overall survival rate was evaluated by follow-up investigation and outpatient review
Time Frame: 1-3 years
|
1-3 years
|
|
The tumor-free survival rate was evaluated by follow-up investigation and outpatient review
Time Frame: 1-3 years
|
1-3 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CT2024-ZJU-OBS7
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Carcinoma, Non-cirrhotic Liver
-
Sun Yat-sen UniversityCompletedHepatocellular Carcinoma(HCC) | Cirrhotic Portal HypertensionChina
-
Omega TherapeuticsRecruitingHepatocellular Carcinoma | Solid Tumor | Liver Cancer | Hepatocellular Carcinoma Non-resectable | Hepatocellular Cancer | Hepatocellular Carcinoma Recurrent | Liver, Cancer of, Non-ResectableUnited States, Hong Kong, Korea, Republic of, Singapore, Taiwan
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)CompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Adult Hepatocellular CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Adult Hepatocellular CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Adult Hepatocellular CarcinomaUnited States
-
Institut für Klinische Krebsforschung IKF GmbH...IpsenRecruitingHepatocellular Carcinoma Non-resectable | Metastatic Hepatocellular CarcinomaGermany
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Adult Hepatocellular Carcinoma | BCLC Stage B Adult Hepatocellular Carcinoma | BCLC Stage C Adult Hepatocellular Carcinoma | BCLC Stage D Adult Hepatocellular Carcinoma | Localized Resectable Adult Liver... and other conditionsUnited States
-
Asan Medical CenterSeoul National University Hospital; Hanyang University; Soon Chun Hyang UniversityRecruitingHepatocellular Carcinoma | Liver Cancer | Hepatocellular Carcinoma Non-resectable | Hepatocellular Cancer | Hepatocellular Carcinoma Stage IVKorea, Republic of
-
ABK BiomedicalRecruitingHepatocellular Carcinoma | Liver Cancer | Hepatocellular Carcinoma Non-resectableUnited States
-
Assistance Publique - Hôpitaux de ParisActive, not recruitingIntrahepatic Non Cirrhotic Portal HypertensionFrance